These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26799295)

  • 1. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.
    Siegal T; Charbit H; Paldor I; Zelikovitch B; Canello T; Benis A; Wong ML; Morokoff AP; Kaye AH; Lavon I
    J Neurosurg; 2016 Oct; 125(4):1008-1015. PubMed ID: 26799295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
    Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
    PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
    Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
    J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
    Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
    AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
    Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
    Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
    Sasayama T; Nishihara M; Kondoh T; Hosoda K; Kohmura E
    Int J Cancer; 2009 Sep; 125(6):1407-13. PubMed ID: 19536818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating Expression Dynamics of miR-21 and miR-10b in Glioblastoma Cells In Vitro: Insights into Responses to Hypoxia and Secretion Mechanisms.
    Charbit H; Lavon I
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
    Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
    Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA is a biomarker for post-operative monitoring in glioma.
    Morokoff A; Jones J; Nguyen H; Ma C; Lasocki A; Gaillard F; Bennett I; Luwor R; Stylli S; Paradiso L; Koldej R; Paldor I; Molania R; Speed TP; Webb A; Infusini G; Li J; Malpas C; Kalincik T; Drummond K; Siegal T; Kaye AH
    J Neurooncol; 2020 Sep; 149(3):391-400. PubMed ID: 32915353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
    Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
    Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
    Narayana A; Golfinos JG; Fischer I; Raza S; Kelly P; Parker E; Knopp EA; Medabalmi P; Zagzag D; Eagan P; Gruber ML
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):383-9. PubMed ID: 18793954
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.